FDA extends Leqembi Iqlik review period to August 24
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioArctic AB (BIOAb)
Assess today's live BioArctic AB (BIOAb) share price, performance and insights using our live Stockholm: BIOAb stock exchange data.
Analyse the historical data and BioArctic AB share price performance charts on this page. Our technical summary section provides analysis on BioArctic share price buy/sell indicators using real-time data (or discuss the BioArctic (BIOAb) stock price today with other investors in the BioArctic ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST BIOAb share price (ISIN: SE0010323311) to enhance your trading decisions with our free investment tools and resources.
What Is the BioArctic AB Share Price Today?
The BioArctic share price today is 309.6000.
What Is the Stock Symbol for BioArctic AB
The stock symbol (or 'ticker') for BioArctic AB is "BIOAb."
What Stock Exchange Does BioArctic AB Trade On?
BioArctic AB is listed and trades on the Stockholm stock exchange.
Is BioArctic AB a Good Stock to Buy?
Determining whether BioArctic AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and BioArctic AB share price performance charts on this page. Our technical summary section provides analysis on BioArctic share price buy/sell indicators using real-time data (or discuss the BioArctic (BIOAb) stock price today with other investors in the BioArctic ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST BIOAb share price (ISIN: SE0010323311) to enhance your trading decisions with our free investment tools and resources.
What Is the BioArctic AB Share Price Today?
The BioArctic share price today is 309.6000.
What Is the Stock Symbol for BioArctic AB
The stock symbol (or 'ticker') for BioArctic AB is "BIOAb."
What Stock Exchange Does BioArctic AB Trade On?
BioArctic AB is listed and trades on the Stockholm stock exchange.
Is BioArctic AB a Good Stock to Buy?
Determining whether BioArctic AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
309.6000
-12.2000(-3.79%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
309.0000
321.8000
52 wk Range
172.9000
364.4000
BIOAb is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
309.0000321.8000
52 wk Range
172.9000364.4000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.63%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.63%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BIOAb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
298.2000
Downside
-3.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price often moves in the opposite direction of the market
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
1 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 298.2000
(-3.68% Downside)
Earnings
Latest Release
20/05/2026
EPS / Forecast
2.39 / -0.23
Revenue / Forecast
437.6M / 190.67M
Compare BIOAb to Peers and Sector
Metrics to compare | BIOAb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOAbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 27.9x | −9.9x | −0.5x | |
PEG Ratio | 0.04 | −0.23 | 0.00 | |
Price/Book | 14.5x | 7.8x | 2.6x | |
Price / LTM Sales | 14.3x | 13.5x | 3.1x | |
Upside (Analyst Target) | −8.5% | 140.8% | 54.0% | |
Fair Value Upside | Unlock | 10.3% | 6.5% | Unlock |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BioArctic (Stockholm: BIOAb) Share Price Today?
The BioArctic stock price today is 309.6000 SEK.
What Stock Exchange Does BioArctic (BIOAb) Trade On?
BioArctic is listed and trades on the Stockholm Stock Exchange.
What Is the Ticker (Stock Symbol) for BioArctic?
The stock symbol (also called a 'ticker') for BioArctic is "BIOAb."
Does BioArctic Pay Dividends? What’s The Current BIOAb Dividend Yield?
Yes, BIOAb Pays Dividends to its Shareholders. The current BioArctic dividend yield is 0.63%.
What Is the Current BioArctic Market Capitalisation?
As of today, BioArctic (Stockholm: BIOAb) market cap is 27.5000B SEK.
What Is BioArctic's (BIOAb) Earnings Per Share (TTM)?
The BioArctic EPS is currently 11.5200 (Trailing Twelve Months).
When Is the Next BioArctic Earnings Date?
BioArctic's next earnings report will be released on 26/08/2026.
Is BIOAb a Buy or Sell From a Technical Analyst Perspective?
Based on today's BioArctic moving averages and other technical indicators, the daily buy/sell signal for BIOAb stock is Strong Sell.
How Many Times Has BioArctic Stock Split?
BioArctic has split 0 times. (See the BIOAb stock split history page for full effective split date and price information.)
How Many Employees Does BioArctic Have?
BioArctic has 129 employees, based on their latest Companies House report.
What is the current trading status of BioArctic (Stockholm: BIOAb)?
As of 21/05/2026, BioArctic (BIOAb) is trading at a share price of 309.6000 SEK, with a previous close of 321.8000 SEK. The stock has fluctuated within a day range of 309.0000 SEK to 321.8000 SEK, while its 52-week range spans from 172.9000 SEK to 364.4000 SEK.
What Is BioArctic (BIOAb) Price Target According to Analysts?
The average 12-month price target for BioArctic is 298.2000 SEK, with a high estimate of 342 SEK and a low estimate of 240 SEK. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -3.68% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.